A non-parametric trim and fill method of accounting for publication bias in meta-analysis
Several mid-stage trials will read out in 2025 to provide important proof points for novel MoAs and their potential for differentiation, e.g., Lillys bimagrumab (activin/myostatin type II receptor inhibitor) in combination with semaglutide, aiming to deliver weight loss while preserving muscle mass (phase 2b)
Minor side effects are rare but can include nausea or mild irritation at the injection site
In TCM, jujube calms the Shen (spirit) and supports immunity, addressing the anxiety and lowered immunity that often accompany nutritional depletion
Women should track ovulatory markers, such as basal body temperature, luteinizing hormone surge kits, and mid-luteal progesterone, alongside serum hormone panels to judge response
MC1R na melanocytach skry steruje syntez eumelaniny ciemnego barwnika o waciwociach fotoochronnych